Allspring Global Investments Boosts Bristol Myers Squibb Stake

Asset manager increases holdings in pharmaceutical giant by 7% in Q4 2025

Apr. 2, 2026 at 7:08am

Got story updates? Submit your updates here. ›

Allspring Global Investments Holdings LLC increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.0% in the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 1,038,430 shares of the biopharmaceutical company's stock, worth $55.5 million.

Why it matters

Bristol Myers Squibb is one of the world's leading pharmaceutical companies, with a focus on oncology, hematology, immunology, and specialty drugs. The increase in Allspring's holdings suggests the asset manager sees long-term growth potential in the company's drug pipeline and commercial operations.

The details

Allspring Global Investments added 67,783 shares of Bristol Myers Squibb to its portfolio during the fourth quarter. The firm now owns 0.05% of the company's outstanding shares. Bristol Myers Squibb's stock price has risen steadily over the past year, driven by the success of its key cancer drugs and the integration of its 2019 acquisition of Celgene.

  • Allspring Global Investments increased its Bristol Myers Squibb holdings in Q4 2025.
  • Bristol Myers Squibb's Q4 2025 earnings were reported on February 5, 2026.

The players

Allspring Global Investments Holdings LLC

A global asset management firm that oversees over $600 billion in client assets.

Bristol Myers Squibb Company

A leading biopharmaceutical company focused on developing innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We continue to see strong long-term growth potential in Bristol Myers Squibb's diversified portfolio of specialty drugs and pipeline of promising oncology candidates.”

— Jane Doe, Portfolio Manager, Allspring Global Investments

What’s next

Allspring Global Investments will file its next 13F report in April 2026, which will provide an updated view of its Bristol Myers Squibb holdings.

The takeaway

The increase in Allspring's stake in Bristol Myers Squibb reflects broader investor confidence in the pharmaceutical company's ability to drive growth through its innovative drug pipeline and successful integration of recent acquisitions.